An approach to cystic kidney diseases: The clinician's view

Nature Reviews Nephrology

Volumn 10, Issue 12, 2014, Pages 687-699

  Kurschat, Christine E ^a   Müller, Roman Ulrich ^a   Franke, Mareike ^a   Maintz, David ^a   Schermer, Bernhard ^a   Benzing, Thomas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BARDET BIEDL SYNDROME; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DIFFERENTIAL DIAGNOSIS; GENETIC SCREENING; HUMAN; JOUBERT SYNDROME; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; MEDICAL DECISION MAKING; MEDULLARY SPONGE KIDNEY; MOLECULAR GENETICS; NEPHROLOGIST; NEPHRONOPHTHISIS; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW; SENIOR LOKEN SYNDROME; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EPIDEMIOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES, CYSTIC; MALE; MULTIMODAL IMAGING; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

BIOPSY, NEEDLE; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES, CYSTIC; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84911960390     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.173     Document Type: Review

References (154)

1. Badano, J. L., Mitsuma, N., Beales, P. L. & Katsanis, N. The ciliopathies: an emerging class of human genetic disorders. Annu. Rev. Genomics Hum. Genet. 7, 125-148 (2006).
2. Fliegauf, M., Benzing, T. & Omran, H. When cilia go bad: cilia defects and ciliopathies. Nat. Rev. Mol. Cell Biol. 8, 880-893 (2007).
3. Gerdes, J. M., Davis, E. E. & Katsanis, N. The vertebrate primary cilium in development, homeostasis, and disease. Cell 137, 32-45 (2009).
4. Hildebrandt, F., Benzing, T. & Katsanis, N. Ciliopathies. N. Engl. J. Med. 364, 1533-1543 (2011).
5. Lee, J. E. & Gleeson, J. G. A systems-biology approach to understanding the ciliopathy disorders. Genome Med. 3, 59 (2011).
6. Goggolidou, P. Wnt and planar cell polarity signaling in cystic renal disease. Organogenesis 10, 86-95 (2013).
7. Yuan, S. & Sun, Z. Expanding horizons: ciliary proteins reach beyond cilia. Annu. Rev. Genet. 47, 353-376 (2013).
8. Coppieters, F., Lefever, S., Leroy, B. P. & De Baere, E. CEP290, a gene with many faces: mutation overview and presentation of CEP290base. Hum. Mutat. 31, 1097-1108 (2010).
9. Torres, V. E. & Harris, P. C. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 76, 149-168 (2009).
10. Harris, P. C. & Torres, V. E. Polycystic kidney disease. Annu. Rev. Med. 60, 321-337 (2009).
11. Stewart, J. H. End-stage renal failure appears earlier in men than in women with polycystic kidney disease. Am. J. Kidney Dis. 24, 181-183 (1994).
12. Hildebrandt, F. Genetic kidney diseases. Lancet 375, 1287-1295 (2010).
13. Torres, V. E., Harris, P. C. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 369, 1287-1301 (2007).
14. Kim, E. & Walz, G. Sensitive cilia set up the kidney. Nat. Med. 13, 1409-1411 (2007).
15. Luciano, R. L. & Dahl, N. K. Extra-renal manifestations of ADPKD: considerations for routine screening and management. Nephrol. Dial. Transplant. 29, 247-254.
16. Torres, V. E. Water for ADPKD? Probably, yes. J. Am. Soc. Nephrol. 17, 2089-2091 (2006).
17. Torres, V. E. et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 10, 363-364 (2004).
18. Nagao, S. et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J. Am. Soc. Nephrol. 17, 2220-2227 (2006).
19. Klahr, S. et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J. Am. Soc. Nephrol. 5, 2037-2047 (1995).
20. Hateboer, N. et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353, 103-107 (1999).
21. O'Toole, J. F. et al. Individuals with mutations in XPNPEP3, which encodes a mitochondrial protein, develop a nephronophthisis-like nephropathy. J. Clin. Invest. 120, 791-802 (2010).
22. Hurd, T. W. et al. Mutation of the Mg2+ transporter SLC41A1 results in a nephronophthisis-like phenotype. J. Am. Soc. Nephrol. 24, 967-977 (2013).
23. Ravine, D., Gibson, R. N., Donlan, J. & Sheffield, L. J. An ultrasound renal cyst prevalence survey: specificity data for inherited renal cystic diseases. Am. J. Kidney Dis. 22, 803-807 (1993).
24. Sun, Y., Zhou, H. & Yang, B. Drug discovery for polycystic kidney disease. Acta Pharmacol. Sin. 32, 805-816 (2011).
25. Badenas, C. et al. Loss of heterozygosity in renal and hepatic epithelial cystic cells from ADPKD1 patients. Eur. J. Hum. Genet. 8, 487-492 (2000).
26. Shillingford, J. M. et al. The mTOR pathway is regulated by polycystin 1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA. 103, 5466-5471 (2006).
27. Hanaoka, K. & Guggino, W. B. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol. 11, 1179-1187 (2000).
28. Grantham, J. J., Ye, M., Gattone, V. H. & Sullivan, L. P. In vitro fluid secretion by epithelium from polycystic kidneys. J. Clin. Invest. 95, 195-202 (1995).
29. Torres, V. E. & Harris, P. C. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J. Am. Soc. Nephrol. 25, 18-32 (2014).
30. Chang, M. Y. et al. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol. Dial. Transplant. 21, 2078-2084 (2006).
31. Griffin, M. D., Torres, V. E., Grande, J. P. & Kumar, R. Vascular expression of polycystin. J. Am. Soc. Nephrol. 8, 616-626 (1997).
32. Griffin, M. D. et al. Expression of polycystin in mouse metanephros and extra-metanephric tissues. Kidney Int. 52, 1196-1205 (1997).
33. Wu, J. et al. Characterization of primary cilia in human airway smooth muscle cells. Chest 136, 561-570 (2009).
34. Sharif-Naeini, R. et al. Polycystin 1 and 2 dosage regulates pressure sensing. Cell 139, 587-596 (2009).
35. Masyuk, A. I. et al. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology 131, 911-920 (2006).
36. Cobben, J. M., Breuning, M. H., Schoots, C., ten Kate, L. P. & Zerres, K. Congenital hepatic fibrosis in autosomal-dominant polycystic kidney disease. Kidney Int. 38, 880-885 (1990).
37. Fick, G. M. et al. The spectrum of autosomal dominant polycystic kidney disease in children. J. Am. Soc. Nephrol. 4, 1654-1660 (1994).
38. Harris, P. C. et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 17, 3013-3019 (2006).
39. Fick-Brosnahan, G. M., Belz, M. M., McFann, K. K., Johnson, A. M. & Schrier, R. W. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am. J. Kidney Dis. 39, 1127-1134 (2002).
40. Johnson, A. M. & Gabow, P. A. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J. Am. Soc. Nephrol. 8, 1560-1567 (1997).
41. Torres, V. E. et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 640-647 (2011).
42. Higashihara, E. et al. Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol. Dial. Transplant. 29, 1710-1719 (2014).
43. Hebert, L. A., Greene, T., Levey, A., Falkenhain, M. E. & Klahr, S. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am. J. Kidney Dis. 41, 962-971 (2003).
44. Ravine, D. et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343, 824-827 (1994).
45. Nicolau, C. et al. Autosomal dominant polycystic kidney disease types 1 and 2: assessment of US sensitivity for diagnosis. Radiology 213, 273-276 (1999).
46. Pei, Y. et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J. Am. Soc. Nephrol. 20, 205-212 (2009).
47. Grantham, J. J. et al. Detected renal cysts are tips of the iceberg in adults with ADPKD. Clin. J. Am. Soc. Nephrol. 7, 1087-1093 (2012).
48. Orskov, B., Sørensen, V. R., Feldt-Rasmussen, B. & Strandgaard, S. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol. Dial. Transplant. 27, 1607-1613 (2012).
49. O'Callaghan, F. J., Noakes, M. J., Martyn, C. N. & Osborne, J. P. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 94, 853-857 (2004).
50. Kaelin, W. G. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673-682 (2002).
51. Gambaro, G., Danza, F. M. & Fabris, A. Medullary sponge kidney. Curr. Opin. Nephrol. Hypertens. 22, 421-426 (2013).
52. Fabris, A., Anglani, F., Lupo, A. & Gambaro, G. Medullary sponge kidney: state of the art. Nephrol. Dial. Transplant. 28, 1111-1119 (2013).
53. Sherstha, R. et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 26, 1282-1286 (1997).
54. Alvaro, D. et al. Estrogens and the pathophysiology of the biliary tree. World J. Gastroenterol. 12, 3537-3545 (2006).
55. Stamm, E. R. et al. Frequency of ovarian cysts in patients with autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 34, 120-124 (1999).
56. Rozenfeld, M. N. et al. Should patients with autosomal dominant polycystic kidney disease be screened for cerebral aneurysms? Am. J. Neuroradiol. 35, 3-9 (2014).
57. Pirson, Y., Chauveau, D. & Torres, V. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 13, 269-276 (2002).
58. Xu, H. W., Yu, S. Q., Mei, C. L. & Li, M. H. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke 42, 204-206 (2011).
59. Irazabal, M. V. et al. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 1274-1285 (2011).
60. Hossack, K. F., Leddy, C. L., Johnson, A. M., Schrier, R. W. & Gabow, P. A. Echocardiographic findings in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 319, 907-912 (1988).
61. Fick, G. M., Johnson, A. M., Hammond, W. S. & Gabow, P. A. Causes of death in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 5, 2048-2056 (1995).
62. Hughes, L. E. Postmortem survey of diverticular disease of the colon. I. Diverticulosis and diverticulitis. Gut 10, 336-344 (1969).
63. Guay-Woodford, L. M. & Desmond, R. A. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 111, 1072-1080 (2003).
64. Bergmann, C. et al. PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD). Hum. Mutat. 23, 453-463 (2004).
65. Fonck, C., Chauveau, D., Gagnadoux, M. F., Pirson, Y. & Grünfeld, J. P. Autosomal recessive polycystic kidney disease in adulthood. Nephrol. Dial. Transplant. 16, 1648-1652 (2001).
66. Adeva, M. et al. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 85, 1-21 (2006).
67. Sweeney, W. E., Jr & Avner, E. D. Diagnosis and management of childhood polycystic kidney disease. Pediatr. Nephrol. 26, 675-692 (2011).
68. Khan, K., Schwarzenberg, S. J., Sharp, H. L., Matas, A. J. & Chavers, B. M. Morbidity from congenital hepatic fibrosis after renal transplantation for autosomal recessive polycystic kidney disease. Am. J. Transplant. 2, 360-365 (2002).
69. Kern, S., Zimmerhackl, L. B., Hildebrandt, F. & Uhl, M. Rare MR urography- A new diagnostic method in autosomal recessive polycystic kidney disease. Acta Radiol. 40, 543-544 (1999).
70. Zerres, K. et al. Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft für Pädiatrische, Nephrologie. Acta Paediatr. 85, 437-445 (1996).
71. Büscher, R. et al. Clinical manifestations of autosomal recessive polycystic kidney disease (ARPKD): kidney-related and non kidney related phenotypes. Pediatr. Nephrol. (2013). http://dx.doi.org/10.1007/s00467 013 2634-1.
72. Hildebrandt, F., Attanasio, M. & Otto, E. Nephronophthisis: Disease Mechanisms of a Ciliopathy. J. Am. Soc. Nephrol. 20, 23-35 (2009).
73. Hildebrandt, F. & Zhou, W. Nephronophthisis-Associated Ciliopathies. J. Am. Soc. Nephrol. 18, 1855-1871 (2007).
74. Salomon, R., Saunier, S. & Niaudet, P. Nephronophthisis. Pediatr. Nephrol. 24, 2333-2344 (2009).
75. Hildebrandt, F. & Otto, E. Cilia and centrosomes: a unifying pathogenic concept for cystic kidney disease? Nat. Rev. Genet. 6, 928-940 (2005).
76. Wolf, M. T. F. & Hildebrandt, F. Nephronophthisis. Pediatr. Nephrol. 26, 181-194 (2011).
77. Halbritter, J. et al. Identification of 99 novel mutations in a worldwide cohort of 1,056 patients with a nephronophthisis-related ciliopathy. Hum. Genet. 132, 865-884 (2013).
78. Nonaka, S. et al. Randomization of left-right asymmetry due to loss of nodal cilia generating leftward flow of extraembryonic fluid in mice lacking KIF3B motor protein. Cell 95, 829-837 (1998).
79. Chen, J., Knowles, H. J., Hebert, J. L. & Hackett, B. P. Mutation of the mouse hepatocyte nuclear factor/forkhead homologue 4 gene results in an absence of cilia and random left-right asymmetry. J. Clin. Invest. 102, 1077-1082 (1998).
80. Schneider, H. & Brueckner, M. Of mice and men: dissecting the genetic pathway that controls left-right asymmetry in mice and humans. Am. J. Med. Genet. 97, 258-270 (2000).
81. Betz, R. et al. Children with ocular motor apraxia type Cogan carry deletions in the gene (NPHP1) for juvenile nephronophthisis. J. Pediatr. 136, 828-831 (2000).
82. Johnson, C. A. Molecular pathology and genetics of congenital hepatorenal fibrocystic syndromes. J. Med. Genet. 40, 311-319 (2003).
83. Mainzer, F., Saldino, R. M., Ozonoff, M. B. & Minagi, H. Familial nephropathy associated with retinitis pigmentosa, cerebellar ataxia and skeletal abnormalities. Am. J. Med. 49, 556-562 (1970).
84. Halbritter, J. et al. Defects in the IFT B component IFT172 cause Jeune and Mainzer-Saldino syndromes in humans. Am. J. Hum. Genet. 93, 915-925 (2013).
85. McInerney-Leo, A. M. et al. Short-rib polydactyly and Jeune syndromes are caused by mutations in WDR60. Am. J. Hum. Genet. 93, 515-523 (2013).
86. Huber, C. et al. WDR34 mutations that cause short-rib polydactyly syndrome type III/severe asphyxiating thoracic dysplasia reveal a role for the NF-B pathway in cilia. Am. J. Hum. Genet. 93, 926-931 (2013).
87. Lin, A. E. et al. Sensenbrenner syndrome (Cranioectodermal dysplasia): clinical and molecular analyses of 39 patients including two new patients. Am. J. Med. Genet. A 161, 2762-2776 (2013).
88. Parisi, M. A. Clinical and molecular features of Joubert syndrome and related disorders. Am. J. Med. Genet. C Semin. Med. Genet. 151, 326-340 (2009).
89. Brancati, F., Dallapiccola, B. & Valente, E. M. Joubert Syndrome and related disorders. Orphanet J. Rare Dis. 5, 20 (2010).
90. Dafinger, C. et al. Mutations in KIF7 link Joubert syndrome with Sonic Hedgehog signaling and microtubule dynamics. J. Clin. Invest. 121, 2662-2667 (2011).
91. O'Dea, D. et al. The importance of renal impairment in the natural history of Bardet-Biedl syndrome. Am. J. Kidney Dis. 27, 776-783 (1996).
92. Imhoff, O. et al. Bardet-Biedl syndrome: a study of the renal and cardiovascular phenotypes in a French cohort. Clin. J. Am. Soc. Nephrol. 6, 22-29 (2011).
93. Putoux, A., Attie-Bitach, T., Martinovic, J. & Gubler, M. C. Phenotypic variability of Bardet-Biedl syndrome: focusing on the kidney. Pediatr. Nephrol. 27, 7-15 (2012).
94. Bergmann, C. Educational paper: ciliopathies. Eur. J. Pediatr. 171, 1285-1300 (2012).
95. Zaghloul, N. A. & Katsanis, N. Mechanistic insights into Bardet-Biedl syndrome, a model ciliopathy. J. Clin. Invest. 119, 428-437 (2009).
96. Bollée, G. et al. Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations. Clin. J. Am. Soc. Nephrol. 6, 2429-2438 (2011).
97. Wolf, M. T. F. et al. Mutations of the Uromodulin gene in MCKD type 2 patients cluster in exon 4, which encodes three EGF-like domains. Kidney Int. 64, 1580-1587 (2003).
98. Scolari, F. et al. Identification of a new locus for medullary cystic disease, on chromosome 16p12. Am. J. Hum. Genet. 64, 1655-1660 (1999).
99. Dahan, K. et al. A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J. Am. Soc. Nephrol. 14, 2883-2893 (2003).
100. Christodoulou, K. et al. Chromosome 1 localization of a gene for autosomal dominant medullary cystic kidney disease. Hum. Mol. Genet. 7, 905-911 (1998).
101. Hart, T. C. et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J. Med. Genet. 39, 882-892 (2002).
102. Kirby, A. et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. Nat. Genet. 45, 299-303 (2013).
103. Zivná, M. et al. Dominant Renin Gene Mutations Associated with Early-Onset Hyperuricemia, Anemia, and Chronic Kidney Failure. Am. J. Hum. Genet. 85, 204-213 (2009).
104. Osborne, J. P., Fryer, A. & Webb, D. Epidemiology of tuberous sclerosis. Ann. N. Y. Acad. Sci. 615, 125-127 (1991).
105. Crino, P. B., Nathanson, K. L. & Henske, E. P. The tuberous sclerosis complex. N. Engl. J. Med. 355, 1345-1356 (2006).
106. Cook, J. A., Oliver, K., Mueller, R. F. & Sampson, J. A cross sectional study of renal involvement in tuberous sclerosis. J. Med. Genet. 33, 480-484 (1996).
107. Rakowski, S. K. et al. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int. 70, 1777-1782 (2006).
108. Shepherd, C. W., Gomez, M. R., Lie, J. T. & Crowson, C. S. Causes of death in patients with tuberous sclerosis. Mayo Clin. Proc. 66, 792-796 (1991).
109. Washecka, R. & Hanna, M. Malignant renal tumors in tuberous sclerosis. Urology 37, 340-343 (1991).
110. Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374-1403 (2013).
111. Kopp, C. M. C., Muzykewicz, D. A., Staley, B. A., Thiele, E. A. & Pulsifer, M. B. Behavior problems in children with tuberous sclerosis complex and parental stress. Epilepsy Behav. 13, 505-510 (2008).
112. Joinson, C. et al. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol. Med. 33, 335-344 (2003).
113. Mizuguchi, M. & Takashima, S. Neuropathology of tuberous sclerosis. Brain Dev. 23, 508-515 (2001).
114. Yates, J. R. W. et al. The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management. Arch. Dis. Child. 96, 1020-1025 (2011).
115. Ryu, J. H. et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am. J. Respir. Crit. Care Med. 173, 105-111 (2006).
116. Webb, D. W., Clarke, A., Fryer, A. & Osborne, J. P. The cutaneous features of tuberous sclerosis: a population study. Br. J. Dermatol. 135, 1-5 (1996).
117. Van Slegtenhorst, M. et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277, 805-808 (1997).
118. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75, 1305-1315 (1993).
119. Rosner, M., Hanneder, M., Siegel, N., Valli, A. & Hengstschläger, M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat. Res. 658, 234-246 (2008).
120. Siroky, B. J., Yin, H. & Bissler, J. J. Clinical and Molecular Insights into Tuberous Sclerosis Complex Renal Disease. Pediatr. Nephrol. 26, 839-852 (2010).
121. Lee, D. F. et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130, 440-455 (2007).
122. Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140-151 (2008).
123. FDA approval for Everolimus, US National Cancer Institute, [online], http://www.cancer.gov/cancertopics/druginfo/fda-everolimus (2014).
124. Franz, D. N. & Weiss, B. D. Molecular therapies for tuberous sclerosis and neurofibromatosis. Curr. Neurol. Neurosci. Rep. 12, 294-301 (2012).
125. Jones, A. C. et al. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum. Mol. Genet. 6, 2155-2161 (1997).
126. Brook-Carter, P. T. et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease- A contiguous gene syndrome. Nat. Genet. 8, 328-332 (1994).
127. Bausch, B. et al. Renal cancer in von Hippel-Lindau disease and related syndromes. Nat. Rev. Nephrol. 9, 529-538 (2013).
128. Neumann, H. P. & Wiestler, O. D. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337, 1052-1054 (1991).
129. Molino, D., Sepe, J., Anastasio, P. & De Santo, N. G. The history of von Hippel-Lindau disease. J. Nephrol. 19, S119-S123 (2006).
130. Siemeister, G. et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56, 2299-2301 (1996).
131. Maher, E. R., Neumann, H. P. & Richard, S. von Hippel-Lindau disease: a clinical and scientific review. Eur. J. Hum. Genet. 19, 617-623 (2011).
132. Maher, E. R. et al. Clinical features and natural history of von Hippel-Lindau disease. Q. J. Med. 77, 1151-1163 (1990).
133. Vogelzang, N. J. & Stadler, W. M. Kidney cancer. Lancet 352, 1691-1696 (1998).
134. Lonser, R. R. et al. von Hippel-Lindau disease. Lancet 361, 2059-2067 (2003).
135. Maddock, I. R. et al. A genetic register for von Hippel-Lindau disease. J. Med. Genet. 33, 120-127 (1996).
136. Bergmann, C. ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. Pediatr. Nephrol. (2014). http://dx.doi.org/10.1007/s00467 013 2706-2.
137. Harris, P. C. & Rossetti, S. Molecular diagnostics for autosomal dominant polycystic kidney disease. Nat. Rev. Nephrol. 6, 197-206 (2010).
138. Woo, Y. M. et al. Genome-wide methylation profiling of ADPKD identified epigenetically regulated genes associated with renal cyst development. Hum. Genet. 133, 281-297 (2014).
139. Daoust, M. C., Reynolds, D. M., Bichet, D. G. & Somlo, S. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomics 25, 733-736 (1995).
140. De Almeida, S. et al. Autosomal dominant polycystic kidney disease: evidence for the existence of a third locus in a Portuguese family. Hum. Genet. 96, 83-88 (1995).
141. Edghill, E. L., Bingham, C., Ellard, S. & Hattersley, A. T. Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J. Med. Genet. 43, 84-90 (2006).
142. Faguer, S. et al. Massively enlarged polycystic kidneys in monozygotic twins with TCF2/HNF-1beta (hepatocyte nuclear factor-1beta) heterozygous whole-gene deletion. Am. J. Kidney Dis. 50, 1023-1027 (2007).
143. Drenth, J. P. H. et al. Abnormal hepatocystin caused by truncating PRKCSH mutations leads to autosomal dominant polycystic liver disease. Hepatology 39, 924-931 (2004).
144. Davila, S. et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat. Genet. 36, 575-577 (2004).
145. Onuchic, L. F. et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin transcription factor domains and parallel beta-helix 1 repeats. Am. J. Hum. Genet. 70, 1305-1317 (2002).
146. Ward, C. J. et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat. Genet. 30, 259-269 (2002).
147. Denamur, E. et al. Genotype-phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease. Kidney Int. 77, 350-358 (2010).
148. Rossetti, S. & Harris, P. C. Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. J. Am. Soc. Nephrol. 18, 1374-1380 (2007).
149. Furu, L. et al. Milder presentation of recessive polycystic kidney disease requires presence of amino acid substitution mutations. J. Am. Soc. Nephrol. 14, 2004-2014 (2003).
150. Bergmann, C. et al. Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). J. Am. Soc. Nephrol. 14, 76-89 (2003).
151. Rossetti, S. et al. A complete mutation screen of PKHD1 in autosomal-recessive polycystic kidney disease (ARPKD) pedigrees. Kidney Int. 64, 391-403 (2003).
152. Harris, P. C. & Rossetti, S. Molecular genetics of autosomal recessive polycystic kidney disease. Mol. Genet. Metab. 81, 75-85 (2004).
153. Romani, M., Micalizzi, A. & Valente, E. M. Joubert syndrome: congenital cerebellar ataxia with the molar tooth. Lancet Neurol. 12, 894-905 (2013).
154. Barker, A. R., Thomas, R. & Dawe, H. R. Meckel-Gruber syndrome and the role of primary cilia in kidney, skeleton, and central nervous system development. Organogenesis 10, 96-107 (2014).